Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Operating Margin (2021 - 2025)

Historic Operating Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 13.28%.

  • Kiniksa Pharmaceuticals International's Operating Margin rose 218900.0% to 13.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.38%, marking a year-over-year increase of 132100.0%. This contributed to the annual value of 10.78% for FY2024, which is 14500.0% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Operating Margin is 13.28%, which was up 218900.0% from 12.86% recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Operating Margin's 5-year high stood at 46.82% during Q3 2022, with a 5-year trough of 526.41% in Q2 2021.
  • Moreover, its 5-year median value for Operating Margin was 12.18% (2024), whereas its average is 62.63%.
  • Its Operating Margin has fluctuated over the past 5 years, first surged by 4546100bps in 2022, then crashed by -631200bps in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Operating Margin stood at 192.75% in 2021, then skyrocketed by 98bps to 4.08% in 2022, then surged by 102bps to 0.1% in 2023, then plummeted by -16315bps to 15.75% in 2024, then skyrocketed by 184bps to 13.28% in 2025.
  • Its Operating Margin stands at 13.28% for Q3 2025, versus 12.86% for Q2 2025 and 9.63% for Q1 2025.